CN107428689A - 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物 - Google Patents

作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物 Download PDF

Info

Publication number
CN107428689A
CN107428689A CN201680016726.1A CN201680016726A CN107428689A CN 107428689 A CN107428689 A CN 107428689A CN 201680016726 A CN201680016726 A CN 201680016726A CN 107428689 A CN107428689 A CN 107428689A
Authority
CN
China
Prior art keywords
compounds
diseases
compound
formula
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680016726.1A
Other languages
English (en)
Chinese (zh)
Inventor
S.勒里希
H.泰勒
S.海特迈尔
K-H.施莱默
J.施坦普富斯
A.希利施
A.特施特根
E.希梅内斯努内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN107428689A publication Critical patent/CN107428689A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN201680016726.1A 2015-03-19 2016-03-15 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物 Pending CN107428689A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15159829 2015-03-19
EP15159829.9 2015-03-19
PCT/EP2016/055496 WO2016146606A1 (de) 2015-03-19 2016-03-15 Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose

Publications (1)

Publication Number Publication Date
CN107428689A true CN107428689A (zh) 2017-12-01

Family

ID=52736868

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680016726.1A Pending CN107428689A (zh) 2015-03-19 2016-03-15 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物

Country Status (7)

Country Link
US (1) US20190119213A1 (enExample)
EP (1) EP3271332A1 (enExample)
JP (1) JP2018509426A (enExample)
CN (1) CN107428689A (enExample)
CA (1) CA2979937A1 (enExample)
HK (1) HK1247615A1 (enExample)
WO (1) WO2016146606A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094268A (zh) * 2018-07-19 2020-05-01 江苏恒瑞医药股份有限公司 一种凝血因子XIa抑制剂及其中间体的制备方法
CN113474348A (zh) * 2018-12-21 2021-10-01 拜耳公司 取代的氧代吡啶衍生物
CN116947818A (zh) * 2023-09-18 2023-10-27 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2922533T3 (es) 2018-04-10 2022-09-16 Bayer Pharma AG Un derivado de oxopiridina sustituido
US20220144848A1 (en) 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490036A (zh) * 2006-05-05 2009-07-22 米伦纽姆医药公司 Xa因子抑制剂
WO2014154794A1 (de) * 2013-03-28 2014-10-02 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung bei der behandlung von herz-kreislauf-erkrankungen
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849109B (zh) * 2013-10-30 2018-01-23 拜耳制药股份公司 取代的氧代吡啶衍生物
EP3197880B1 (de) * 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
WO2016046166A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2712886T3 (es) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197889B1 (de) * 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CA2961981A1 (en) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) * 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
AU2017317988B2 (en) * 2016-08-31 2020-12-24 Jiangsu Hengrui Medicine Co., Ltd. Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490036A (zh) * 2006-05-05 2009-07-22 米伦纽姆医药公司 Xa因子抑制剂
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2014154794A1 (de) * 2013-03-28 2014-10-02 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung bei der behandlung von herz-kreislauf-erkrankungen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094268A (zh) * 2018-07-19 2020-05-01 江苏恒瑞医药股份有限公司 一种凝血因子XIa抑制剂及其中间体的制备方法
CN113474348A (zh) * 2018-12-21 2021-10-01 拜耳公司 取代的氧代吡啶衍生物
CN116947818A (zh) * 2023-09-18 2023-10-27 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Also Published As

Publication number Publication date
HK1247615A1 (zh) 2018-09-28
JP2018509426A (ja) 2018-04-05
EP3271332A1 (de) 2018-01-24
WO2016146606A1 (de) 2016-09-22
US20190119213A1 (en) 2019-04-25
CA2979937A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
CN105555767B (zh) 取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
CN106687458B (zh) 取代的氧代吡啶衍生物
CN105849109B (zh) 取代的氧代吡啶衍生物
US10138236B2 (en) Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US10071995B2 (en) Substituted oxopyridine derivatives
US10414731B2 (en) Substituted oxopyridine derivatives
US10077265B2 (en) Substituted oxopyridine derivatives
CN107428689A (zh) 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物
US20180250280A1 (en) Substituted oxopyridine derivatives
CN111902414B (zh) 取代的氧代吡啶衍生物
RU2792645C2 (ru) Замещенное оксопиридиновое производное
HK1237777A1 (en) Substituted oxopyridine derivatives
HK40034268A (en) A substituted oxopyridine derivative
HK1227852A1 (en) Substituted oxopyridine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247615

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1247615

Country of ref document: HK